Neuraxpharm Group has taken a significant step in its international expansion with the establishment of a new headquarters in Dubai, called Neuraxpharm Middle East. This new center will operate in six countries of the Gulf Cooperation Council: Saudi Arabia, the United Arab Emirates, Bahrain, Qatar, Kuwait, and Oman. This development is part of a broader strategy aimed at strengthening its presence in high-growth markets, consolidating itself as a key player in the distribution of pharmaceuticals in the region.
The inauguration of Neuraxpharm Middle East joins a prolific year for the company, which had already expanded its operations in Latin America with new subsidiaries in Brazil and Mexico. Now, the focus is shifting towards growth in the Middle East, where the pharmaceutical company plans to launch the prescription medication Briumvi (Ublituximab), designed to treat adults with relapsing forms of multiple sclerosis. This approach not only increases the company’s capacity to compete in a diverse market but also reflects a serious commitment to the health needs in the region.
Neuraxpharm Middle East: A New Era in Pharmaceutical Distribution
The opening of Neuraxpharm Middle East is not just a strategic move, but also aims to facilitate the distribution and sale of Briumvi in the region. This medication is intended for adult patients suffering from active and recurrent multiple sclerosis. Currently, the pharmaceutical company has submitted the drug for approval in Saudi Arabia and the United Arab Emirates, with the goal of officially launching it in the market in 2025. The incorporation of this medication is particularly relevant, as it is expected to meet a significant demand for effective treatments for this chronic disease.
Neuraxpharm’s commitment to the health and well-being of patients is evident in its approach to establishing a direct link between research and the market. By having a local headquarters in Dubai, the company not only improves its logistics and distribution but also allows for a better understanding of the specific needs of patients in Gulf countries. This local approach as part of a global strategy positions Neuraxpharm as a leader in central nervous system (CNS) care in the region.
Furthermore, the establishment of a base in the Middle East strengthens the company’s growth strategy, which seeks to establish operations in markets with high development potential. By offering differentiated products tailored to the culture and health needs of the region, Neuraxpharm is in a privileged position to capture a significant share of the pharmaceutical market.
Growth and Consolidation Strategy in New Markets
The chief executive officer of Neuraxpharm, Jörg-Thomas Dierks, has stated that a key pillar of their strategy is to establish their own operations in high-growth markets. This approach aims not only to expand their geographical reach but also to consolidate their position as a specialist in the central nervous system. This type of strategy is essential in a competitive environment that demands innovation and adaptability.
With approximately one thousand employees, Neuraxpharm is dedicated to the development and marketing of drugs that address various conditions of the CNS. By diversifying its international presence in more than twenty European countries, alongside its operations in Latin America and now in the Middle East, the company seeks to maximize its impact in the global pharmaceutical sector. This model shows how a company can grow by consolidating its expertise in specific areas while adapting to the demands of new regulatory and healthcare environments.
Entering new markets such as those of the Gulf Cooperation Council is not merely a territorial expansion. It also entails a high level of responsibility regarding the quality of the products offered, compliance with regulations, and responsiveness to local needs. Neuraxpharm appears to be well positioned to meet these challenges, which will allow them to make a significant contribution to improving patient health in the Middle East and other regions in the future.
With this new phase, Neuraxpharm not only reinforces its mission to offer quality treatments but also positions itself as a benchmark in the field of pharmacology specialized in the central nervous system. As it advances towards the launch of Briumvi and the consolidation of its operations in the Middle East, the future looks promising for this pharmaceutical company that continues to grow and evolve in a changing global market.
